Individualized Pharmaceutical-care in Outpatients With Cancer Pain

Impact of Individualized Pharmaceutical-care on Medication Adherence and Outcome of Cancer Pain in Opioid-tolerant Outpatients

The purpose of the study is to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant outpatients

This study is a prospective multicenter randomized controlled study to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant outpatients treated with sustained released morphine, oxycodone, and transdermal fentanyl.

Inclusion Criteria:

• Patients aged 18 years or older;
• Histologically confirmed solid tumor;
• Diagnosed chronic cancer pain;
• Opioid-tolerant patients;
• Overall survival is expected to be over 3 months;
• Karnofsky performance score≥50;
• Willing and able to comply with the protocol

Exclusion Criteria:

• Patients aged 18 years or older;
• Histologically confirmed solid tumor;
• Diagnosed chronic cancer pain;
• Opioid-tolerant patients;
• Overall survival is expected to be over 3 months;
• Karnofsky performance score≥50;
• Willing and able to comply with the protocol